J
Julie C. Yates
Researcher at Research Triangle Park
Publications - 85
Citations - 13355
Julie C. Yates is an academic researcher from Research Triangle Park. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 39, co-authored 84 publications receiving 12173 citations. Previous affiliations of Julie C. Yates include GlaxoSmithKline & RAND Corporation.
Papers
More filters
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
Characterisation of COPD heterogeneity in the ECLIPSE cohort
Alvar Agusti,Peter M.A. Calverley,Bartolome R. Celli,Harvey O. Coxson,Lisa D. Edwards,David A. Lomas,William MacNee,Bruce E. Miller,S.I. Rennard,Edwin K. Silverman,Ruth Tal-Singer,Emiel F.M. Wouters,Julie C. Yates,Jørgen Vestbo +13 more
TL;DR: The clinical manifestations of COPD are highly variable and the degree of airflow limitation does not capture the heterogeneity of the disease.
Journal ArticleDOI
Changes in forced expiratory volume in 1 second over time in copd
Jørgen Vestbo,Jørgen Vestbo,Lisa D. Edwards,Paul D. Scanlon,Julie C. Yates,Alvar Agusti,Per Bakke,Peter M.A. Calverley,Bartolome R. Celli,Harvey O. Coxson,Courtney Crim,David A. Lomas,William MacNee,Bruce E. Miller,Edwin K. Silverman,Ruth Tal-Singer,Emiel F.M. Wouters,Stephen I. Rennard +17 more
TL;DR: The rate of change in FEV(1) among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema.
Journal ArticleDOI
Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease Results from the TORCH Study
Bartolome R. Celli,Nicola E. Thomas,Julie A. Anderson,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Jørgen Vestbo,Katharine Knobil,Julie C. Yates,Peter M.A. Calverley +9 more
TL;DR: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression.
Journal ArticleDOI
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.
Alvar Agusti,Lisa D. Edwards,Stephen I. Rennard,William MacNee,Ruth Tal-Singer,Bruce E. Miller,Jørgen Vestbo,Jørgen Vestbo,David A. Lomas,Peter M.A. Calverley,Emiel F.M. Wouters,Courtney Crim,Julie C. Yates,Edwin K. Silverman,Harvey O. Coxson,Per Bakke,Ruth J. Mayer,Bartolome R. Celli +17 more
TL;DR: Overall, the results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment and show associations but do not prove causality.